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OBJECTIVE: To describe urinary tract infection (UTI) treatment among Veterans Affairs 
(VA) Community Living Centers (CLCs) nationally and assess trends in antibiotic use. 
DESIGN: Descriptive study. 
SETTING AND PARTICIPANTS: All UTI episodes treated from 2013-2017 among 
residents in 110 VA CLCs. UTI episodes required collection of a urine culture, antibiotic 
treatment, and a UTI diagnosis code. UTI episodes were stratified into culture-positive 
and negative. 
METHODS: Frequency and rate of antibiotic use were assessed for all UTI episodes 
overall and stratified by culture-positive and negative episodes. Joinpoint Software was 
used for regression analyses of trends over time. 
RESULTS:  We identified 28,247 UTI episodes in 14,983 Veterans. The average age of 
Veterans was 75.7 and 95.9% were male. About half (45.7%) of UTI episodes were 
culture-positive and 25.7% were culture-negative. Escherichia coli was recovered in 
34.1% of culture-positive UTI episodes, followed by Proteus mirabilis and Klebsiella 
recovered in 24.5% and 17.4% of culture-positive UTI episodes, respectively. The rate 
of total antibiotic use in DOT/1,000 bed days decreased by 10.1% per year (95% CI -
13.6 - -6.5%) and fluoroquinolone use (ciprofloxacin or levofloxacin) decreased by 
14.5% per year (95% CI -20.6 - -7.8%) among UTI episodes overall. Similar reductions 
in rates of total antibiotic use and fluoroquinolone use were observed among culture-
positive and among culture-negative UTI episodes. 
 CONCLUSION:  
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Over a 5-year period, antibiotic use for UTIs significantly decreased among VA CLCs, 
as did use of fluoroquinolones. Antibiotic stewardship efforts across VA CLCs should be 




Antibiotics are among the most frequently used medications in long-term care facilities 
(LTCFs), however up to 75% of antibiotic use in LTCFs may be inappropriate.1,2 The 
greatest contributor to inappropriate antibiotic use in LTCFs is the misuse of antibiotics 
for urinary tract infections (UTIs).2-7 The most common problem in the treatment of UTIs 
among residents is misdiagnosis and treatment of asymptomatic bacteriuria with 
antibiotics.8 Another common problem is the use of agents that are overly broad-
spectrum or carry an increased risk of adverse drug events, such as fluoroquinolones.9 
Data from 2010 and more recent data from 2014-2016 demonstrate that 
fluoroquinolones are the most commonly used agents used for treatment of UTI among 
LTCF residents.9-11 This has been in spite of recommendations specific to LTCF 
residents which call for restricted use of fluoroquinolones due to their risk for Clostridium 
difficile infection, adverse drug events, and selection of resistance since 2000.12,13 Per 
2004 and 2011 treatment guidelines of the Infectious Diseases Society of America 
(IDSA), labeled warnings from the Food and Drug Administration, and expert opinion, 
fluoroquinolones should only be used for the treatment of acute cystitis when other UTI 
antibiotics cannot be used due to their propensity for collateral damage.14-16   
 
While previous research suggests that antibiotic selection for UTIs may often be 
suboptimal, large-scale studies of how LTCF residents are treated for UTIs nationally 
are limited. Quantifying how UTIs are treated is a first step in improving the use of 
antibiotics.17  Knowledge of the most commonly used antibiotic agents and the trends in 
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use can inform future efforts to optimize antibiotic use among LTCF residents nationally. 
Such data can also identify problem areas, allowing the development of targeted 
interventions to improve antibiotic use, ultimately improving the care of residents with 
UTIs.  As such, the aim of this work was to describe antibiotic use for UTI among all VA 
LTCFs (known as Community Living Centers or CLCs) nationally from 2013 to 2017 and 
assess trends in antibiotic use.  
 
METHODS 
We conducted a retrospective study using national VA microbiology and pharmacy data 
accessed through the VA Informatics and Computing Infrastructure (VINCI). We 
included all adult (age >18 years) residents with a UTI episode during an inpatient stay 
in a VA CLC unit between January 2013 to December 2017. Three inclusion criteria 
were applied to identify episodes of UTI: (1) collection of urine culture, (2) initiation of a 
UTI-related antibiotic on the date the urine culture was taken or within the 3 days after 
culture collection, and (3) a diagnosis code for UTI (International Classification of 
Diseases, 9th or 10th edition).18  
 
We excluded episodes that likely represented treatment of asymptomatic bacteriuria for 
urologic procedure or pregnancy.19 Urologic procedures (e.g. transurethral resection of 
the prostate, prostate biopsy, cycstoscopy, urodynamic surgery) were identified using 
previously reported diagnosis and procedure codes and using text searches of 
procedure names.20,21 All residents with a urologic produce that occurred within 2 weeks 
of the date of the index urine culture were excluded. We also excluded women of 
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childbearing age (females < 45 years at the time of urine culture). To avoid capturing 
treatment of another potential infection, we excluded episodes in which another positive 
culture (i.e. blood, respiratory, tissue, bone) was identified within 3 days of the index 
culture, unless it was a positive blood culture for the same organism growing in the 
urine.22 In the case of multiple UTI episodes during the study period, we excluded 
subsequent UTI episodes within 30 days of the first episode.   
 
UTI episodes were stratified by urine culture results into culture-negative, culture-
positive, and other episodes. Culture-negative UTI episodes were those in which no 
growth was identified from the urine culture. Culture-positive UTI episodes were defined 
as those in which no more than two typical uropathogens (Escherichia coli, Proteus 
mirabilis, Klebsiella species [spp], Pseudomonas aeruginosa, Providencia spp, 
Enterobacter spp, Citrobacter spp., Morganella morganii, Serratia marcescens, 
Enterococcus spp, Staphylococcus aureus) were isolated with quantitative counts > 105 
CFU/mL from the urine culture.14,19,23,24 Uropathogens of interest were chosen based on 
earlier work indicating these were the most frequently isolated organisms from urine 
samples obtained from LTCF residents.25 All other UTI episodes were defined as those 
in which typical uropathogens were isolated with low quantitative counts (< 105 
CFU/mL), more than two uropathogens were identified, or any other organisms were 
isolated from the urine culture. 
 
We quantified the frequency and rate of antibiotic use for all UTI episodes overall and 
stratified by culture-positive and culture-negative UTI episodes. Frequency of use was 
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the proportion of the number UTI episodes treated with a specific antibiotic agent/class 
divided by the total number of UTI episodes that met study criteria as defined above.  
The rate of antibiotic use was defined as antibiotic days of therapy (DOT).22 One DOT 
represents administration of a single agent on a given day regardless of frequency, 
dose, or route of administration. For each UTI episode, we calculated the DOT for each 
antibiotic used from the start to the end of the treatment up to 30-days post-treatment 
start. End of treatment was identified from gaps in antibiotic therapy of more than 2 
consecutive calendar days. 
 
We summed all UTI specific antibiotic use for our study cohort and standardized it to 
1,000 bed days of care (DOT/1,000 bed days). Antibiotics were grouped into the 
following classes: typical genitourinary tract agents (nitrofurantoin, sulfamethoxazole/ 
trimethoprim, fosfomycin, trimethoprim), fluoroquinolones (ciprofloxacin, levofloxacin), 
1st-2nd generation cephalosporins (cefaclor, cefazolin, cefotetan, cefoxitin, cefuroxime, 
cephalexin), 3rd-4th generation cephalosporins (cefdinir, cefepime, cefixime, cefotaxime, 
cefpodoxime, ceftazidime, ceftriaxone), aminopenicillins (amoxicillin, ampicillin, 
amoxicillin/clavulanate, amipicillin/sulbactam), carbapenems and piperacillin/ 
tazobactam (imipenem, meropenem, ertapenem, doripenem, piperacillin/ tazobactam), 
other multidrug resistant [MDR] gram-negative agents (amikacin, gentamicin, 
tobramycin, avibactam/ceftazidime, aztreonam,  ceftazidime\avibactam, tigecycline), 
anti-methicillin resistant Staphylococcus aureus [MRSA] directed agents (ceftaroline, 
daptomycin, linezolid, vancomycin), and other agents. 
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We identified time trends over the study period using joinpoint regression models.  The 
Joinpoint Regression Program version 4.6.0.0 (National Cancer Institute, Bethesda, 
MD, USA) was used to calculate average annual percent change (AAPC) and 95% 
confidence intervals (CI).26  Significance was set at p<0.05. The AAPC is a weighted 
average of the average percent change (APC) segments from a joinpoint model with the 
weights equal to the duration of each APC segment.    
 
RESULTS 
We identified a total of 28,247 UTI episodes diagnosed and treated with antibiotics 
within 3 days of urine culture among 14,983 Veterans admitted to 110 VA CLCs 
nationally. The median number of UTI episodes per Veteran was 1.0 (interquartile range 
[IQR] 1-2) and the median length of stay among unique Veteran admissions (n=15,829) 
was 127 days (IQR 43-717). At the time of the first UTI episode, the average age of 
Veterans was 75.7 years (+/- 11.5 standard deviation) and 95.9% (n=14,363) were 
male. Additional baseline characteristics are presented in Table 1.   
 
Urine culture results are presented in Table 2. Approximately half of UTI episodes were 
culture-positive (n=12,905, 45.7%) and 25.7% (n=7,265) were culture-negative. 
Escherichia coli was recovered in 34.1% (n=4,400) of culture-positive UTI episodes, 
followed by Proteus mirabilis and Klebsiella spp. recovered in 24.5% (n=3,160) and 
17.4% (n=2,244) of culture-positive UTI episodes, respectively. 
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Among all UTI episodes, the most frequently used antibiotic agents were ciprofloxacin 
(31.2%, n=8,818), sulfamethoxazole/trimethoprim (20.9%, n=5,908), and ceftriaxone 
(16.3%, n=4,591, Table 3). Ciprofloxacin, sulfamethoxazole/trimethoprim, and 
ceftriaxone also had the greatest usage in DOT, accounting for 19.4% (DOT=57,579), 
14.6% (DOT=43,244), and 8.2% (n=24,231) of the total DOT used, respectively. Use of 
broad-spectrum intravenous antibiotic agents accounted for approximately 20% of the 
total DOT used. The rate of total antibiotic use decreased significantly by 10.1% per 
year (95% CI -13.6 – -6.5%) from 20.7 DOT/1,000 bed days in 2013 to 13.2 DOT/1,000 
bed days in 2017. The rate of fluoroquinolone (ciprofloxacin and levofloxacin) use in 
DOT/1,000 bed days decreased significantly by 14.5% per year (95% CI -20.6 – -7.8%). 
The proportion of UTI episodes treated with fluoroquinolones decreased significantly by 
6.0% per year (95% CI -10.4 – -1.3%) over the study period. Fluoroquinolones were 
used in 44.2% (n=2,958/6,693) of suspected UTI episodes in 2013 and in 35.2% of 
episodes in 2017 (n=1,645/4,675).   
 
Among culture-positive UTI episodes, ciprofloxacin (33.5%, n=4,323), 
sulfamethoxazole/ trimethoprim (23.4%, n=3,015), and ceftriaxone (16.7%, n=2,149) 
remained the most frequently used antibiotic agents. Several significant changes in the 
rate of antibiotic use for culture-positive UTI episodes were observed (Figure 1). The 
rate of total antibiotic use for culture-positive episodes decreased significantly by 9.6% 
per year (95% CI -13.1 – -6.0%). The rate of fluoroquinolone use decreased significantly 
by 14.9% per year (95% CI -22.0 – -7.3%).   
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Among culture-negative UTI episodes, ciprofloxacin (26.1%, n=1,899), 
sulfamethoxazole/ trimethoprim (16.6%, n=1,203), and ceftriaxone (16.1%, n=1,167) 
also remained the most frequently used antibiotic agents. Among culture-negative UTI 
episodes, 19,376 fluoroquinolone DOT were used, accounting for 25.4% of all 
fluoroquinolone use (DOT=76,162). Trends in antibiotic use for culture-negative UTI 
episodes are presented in Figure 2. Significant reductions in the rates of total antibiotic 
use (by 11.2% per year, 95% CI -14.8 – -7.4%) and fluoroquinolone use (by 14.8% per 
year, 95% CI -19.6 – -9.7%) were observed. 
 
DISCUSSION 
In our study of about 15,000 Veterans diagnosed and treated for UTIs in CLCs 
nationally, fluoroquinolone use decreased, as did overall antibiotic days of therapy.  
Results stratified by culture-positive and culture-negative UTI episodes were similar.  
 
Ciprofloxacin, sulfamethoxazole/trimethoprim, and ceftriaxone were the most commonly 
used antibiotic agents. Previous work among Veteran cohorts from outpatient and acute 
care inpatient settings have also found that these agents are among the most 
commonly used antibiotics for UTI.27,28 Data from non-VA LTCFs has similarly identified 
fluoroquinolones as the most commonly used antibiotic class for UTIs.9-11  
 
As expected, the typical uropathogens, including E. coli, Proteus, and Klebsiella spp., 
were the most commonly identified uropathogens among culture-positive UTI 
episodes.31 Similar to our findings, E. coli was the most common (53.6%) organism 
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identified among 240 episodes of UTI among residents in 5 Connecticut LTCF, followed 
by Proteus spp (14.6%) and Klebsiella spp (13.9%).25 About 25% of the UTI episodes in 
our study were culture-negative, and suggest potential overtreatment. Previous work 
has confirmed the overtreatment of UTI, in both the presence and absence of positive 
urine cultures, among older adults without symptoms of a UTI. In a study of 153 older 
women diagnosed with a UTI, only 87 (57%) had microbiological evidence of a UTI, yet 
95% of the 66 patients with negative cultures received antibiotics.32   
 
While our work does suggest potential overtreatment, our work also demonstrated 
several impressive reductions in the use of antibiotics for UTI in VA CLCs nationally. We 
found that total antibiotic use decreased by approximately 10% per year from 2013 to 
2017 for all UTI episodes, and by 10% among culture-positive episodes and 11% 
among culture-negative episodes. Improving the diagnosis and treatment of UTIs is a 
well-recognized antibiotic stewardship target among LTCFs.33  Among VA medical 
centers, previous work has confirmed an increase antibiotic stewardship over the study 
period.34  However, there may be facility level or regional variation in application of 
antibiotic stewardship principles, which warrant future investigation. Previous work has 
demonstrated variation in antibiotic use at the facility and regional levels in non-VA 
LTCFs and in VA facilities.35-37   
 
Another encouraging trend we observed was the decrease in fluoroquinolone use 
among all UTI episodes overall and stratified by culture-positive and culture-negative 
episodes. Overall the proportion of UTI episodes treated with fluoroquinolones 
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decreased by 6.0% each year, as did the rate of fluoroquinolones use (by 14.5%). 
Reductions in use may be related to growing evidence on fluoroquinolone-related 
adverse effects, especially in older patients.16,38  In 2008, a boxed warning for an 
increased risk of tendinitis and tendon rupture with fluoroquinolones was mandated by 
the Food and Drug Administration (FDA). Since that time, the FDA has issued warnings 
for other serious adverse effects, including exacerbation of myasthenia gravis, C. 
difficile infection, QT-interval prolongation, severe hypoglycemia, and mental health 
effects.38 In 2013 the FDA updated label warnings for fluoroquinolones and in 2016 the 
FDA specifically recommended use of fluoroquinolones be avoided for uncomplicated 
UTIs, unless no alternative treatment options were available.16  Nitrofurantoin and 
sulfamethoxazole/trimethoprim are suggested empiric UTI treatment options for older 
patients without complicated coexisting conditions and mild UTI symptoms.13,41,42  
However, nitrofurantoin should be avoided in patients with pyelonephritis or a history of 
UTI due to P. mirabilis. Given the high prevalence of P. mirabilis we observed across 
VA nursing homes nationally, our results suggest avoidance of nitrofurantoin as empiric 
therapy, however local resistance patterns should guide empiric therapy. Nitrofurantoin 
may be an option once urine culture results are available. 
 
While fluoroquinolone use decreased over the study period, our results demonstrated 
that fluoroquinolones are still a preferred treatment choice. Fluoroquinolones 
remained the most frequently used antibiotic class for UTIs over the entire study period, 
even in 2017 (35.5% of episodes). These findings may be related to our complicated 
study population of mostly older male Veterans. All urinary tract infections in males are 
 14 
generally considered complicated.19,23  Moreover, approximately 45% of Veterans in our 
study had comorbid benign prostatic hyperplasia, which may lead to complicated UTIs 
and prostatitis due to obstructed and turbulent urine flow.39 Fluoroquinolones achieve 
reliable tissue concentrations in the prostate and are considered first-line in men with 
severe UTI symptoms or concern for prostate involvement.39 While our findings do 
demonstrate impressive reductions in fluoroquinolone use for UTIs among VA CLCs 
nationally, there may be room for further improvement in reducing fluoroquinolone use.  
Focused antibiotic stewardship efforts to further fluoroquinolone use which have been 
successful in single center studies include the removal of fluoroquinolones from local 
formularies and order sets.40,41 Overall, about 76,000 fluoroquinolone DOT were used 
over our study period, and 25% of that use was for culture-negative UTI episodes. Thus, 
negative cultures may be an easy target for antibiotic stewardship in CLCs to further 
reduce fluoroquinolone use in residents who do not have symptoms of urinary infection.   
 
There are limitations to this retrospective study. We defined UTIs as a urine culture plus 
antibiotic treatment in the presence of a UTI diagnosis code. We were unable to capture 
treatment practices for UTIs in which no cultures were obtained, that were culture-
positive and treated without a UTI diagnosis code, or that were treated outside the VA 
CLC setting. We assumed that antibiotic administrations were intended for the treatment 
of a UTI, since antibiotic indication is often missing. To minimize the possibility of 
treatment for anther infection type, we excluded UTI episodes in which there were 
concomitant positive cultures from other sources and required a diagnosis code for UTI. 
Another limitation is we were interested in the real-world treatment of UTIs, we did not 
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attempt to distinguish treatment of asymptomatic bacteriuria versus truly symptomatic 
UTI. We did attempt to exclude asymptomatic bacteriuria in the presence of urologic 
procedure or pregnancy. Additionally, we were unable to capture urinary catheter use 
and thus unable to quantify the prevalence of caterer use in our population. It is possible 
that catheter use declined over the study period and may account in part for the 
observed decreases in antibiotic use. Finally, the generalizability of our findings to other 
populations may be limited, as our population is predominantly male. 
 
In conclusion, our study of over 28,000 UTI episodes in VA CLCs nationally 
demonstrated a decrease in overall antibiotic use for UTIs, including the use of 
fluoroquinolone antibiotics. Antibiotic stewardship efforts across VA CLCs should be 
applauded and should continue to be an ongoing effort, especially in reducing the 
overtreatment of UTI, in both the presence and absence of positive urine cultures, in 
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Table 1.   Baseline characteristics of Veterans admitted to VA nursing homes 
nationally with treated urinary tract infection  
Characteristic Number Percent 
Demographics   
Age in years (mean, standard deviation)a 75.7 11.5 
Male gender 14,363 95.9 
Comorbidities   
    Hypertension 11,399 76.1 
    Dementia 9,076 60.6 
    Diabetes   7,143 47.7 
    Benign prostatic hyperplasia   6,791 45.3 
    Atherosclerosis   6,467 43.2 
    Nutritional deficiencies 6,370 42.5 
    Chronic respiratory disease 6,124 40.9 
    Congestive heart failure 4,980 33.2 
    Chronic renal disease 5,069 33.8 
    Complication of device, implant or graftb 2,587 17.3 
    Adverse effects of medical carec 1,681 11.2 
         
Data are presented as the number and percent, unless otherwise indicated. 
Characteristics presented for 14,983 unique Veterans at the time of the first UTI episode 
included over the study period.   
a Age measured at time of urine culture collection  
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b Includes breakdown, leakage, or complication of urinary catheter  
c Includes all misadventures to patients during surgical or medical care, medical devices 
associated with adverse incidents in diagnostic and therapeutic use, and surgical or 
medical care causing abnormal reaction or complication to the patient, such as urinary 
catherization as a cause of complication.  
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Table 2.  Urine culture results obtained from 28,247 episodes of urinary tract 
infections in VA Community Living Centers nationally, 2013 to 2017 
Organism Frequency (n) Percent (%) 
Culture-positive 12,905 45.7 
     Escherichia coli   4,400 34.1 
     Proteus mirabilis      3,160 24.5 
     Klebsiella spp. 2,244 17.4 
     Pseudomonas aeruginosa        1,136 8.8 
     Providencia spp. 526 4.1 
     Enterobacter spp. 404 3.1 
     Citrobacter spp. 305 2.4 
     Morganella morganii       300 2.3 
     Serratia marcescens       126 1.0 
     Enterococcus spp. 1,403 10.9 
     Staphylococcus aureus       594 4.6 
Culture-negative 7,265 25.7 
Other 8,077 28.6 
 
Spp= species  
Culture-positive UTI episodes were defined as those in which no more than two typical 
uropathogens were isolated with quantitative counts > 105 CFU/mL from the urine 
culture. 
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Culture-negative UTI episodes were those in which no growth was identified from the 
urine culture.  
All other UTI episodes were defined as those in which typical uropathogens were 
isolated with low quantitative counts (< 105 CFU/mL), more than two uropathogens were 
identified, or any other organisms were isolated from the urine culture. 
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Table 3.  Antibiotic use by agent for urinary tract infections in VA Community 
Living Centers nationally, 2013 to 2017 
Antibiotic agent 
Antibiotic use 





use (%)  
Frequency 




Ciprofloxacin 57,579 19.4 8,818 31.2 
Sulfamethoxazole/ 
Trimethoprim 43,244 14.6 5,908 20.9 
Ceftriaxone 24,231 8.2 4,591 16.3 
Amoxicillin/ 
clavulanate 22,873 7.7 3,161 11.2 
Cephalexin 18,855 6.4 2,566 9.1 
Levofloxacin 18,583 6.3 3,179 11.3 
Piperacillin/ 
tazobactam  17,659 6.0 2,983 10.6 
Nitrofurantoin  15,222 5.1 1,953 6.9 
Cefpodoxime  9,431 3.2 1,242 4.4 
Vancomycin  8,312 2.8 1,120 4.0 
Amoxicillin  7,849 2.7 1,036 3.7 
Cefepime 7,711 2.6 1,200 4.2 
Ertapenem 7,487 2.5 934 3.3 
Cefuroxime  7,326 2.5 934 3.3 
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Other agents - 
<2% of total 
DOT  - 
Exposure in 
<2% of UTI 
episodes 




DOT= Days of therapy; UTI= Urinary tract infection  
Frequency of antibiotic use is not mutually exclusive, as UTI episodes could be treated 
with more than one antibiotic. 
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Figure 1.  Trends in rate of antibiotic use among culture-positive urinary tract 





AAPC= average annual percent change; CI=confidence interval; UTI= urinary tract 
infection; MDR= Multidrug resistant; MRSA= methicillin resistant Staphylococcus aureus 
AAPCs represent the average percent change per year in rate of antibiotic use in DOT 
per 1,000 bed days; *=Significant trend at p<0.05 
Solid blue columns represent the rate of antibiotic use per year in DOT per 1,000 bed 
days (range 9.4 to 6.2 DOT/1,000 bed days)  
Lines with markers represent the rate of antibiotic use by class per year in DOT per 




Figure 2. Trends in rate of antibiotic use among culture-negative urinary tract 




AAPC= average annual percent change; CI=confidence interval; DOT= Days of therapy;  
UTI= urinary tract infection; MDR= Multidrug resistant 
 
AAPCs represent the average percent change per year in rate of antibiotic use in DOT 
per 1,000 bed days; *=Significant trend at p<0.05 
Solid blue columns represent the rate of all antibiotic use per year in DOT per 1,000 bed 
days (range 4.8 to 2.9 DOT/1,000 bed days)  
Lines with markers represent the rate of antibiotic use by class per year in DOT per 
1,000 bed days 
 
 
 
